Abivax SA American Depositary Shares
$ 112.70
-3.49%
05 Mar - close price
- Market Cap 8,187,962,000 USD
- Current Price $ 112.70
- High / Low $ 116.45 / 111.25
- Stock P/E N/A
- Book Value -0.76
- EPS -3.58
- Next Earning Report 2026-03-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.58 %
- ROE -5.00 %
- 52 Week High 148.83
- 52 Week Low 4.77
About
Abivax SA is a clinical-stage biotechnology company dedicated to advancing innovative immunotherapies for chronic inflammatory diseases and viral infections. Its lead product candidate, ABX464, is undergoing clinical trials for ulcerative colitis and potentially other therapeutic indications, indicating a strong focus on addressing major unmet medical needs. By leveraging a unique approach that combines antibody-mediated treatments with proprietary compounds, Abivax aims to significantly improve patient outcomes. With a robust development pipeline and a committed scientific team, Abivax presents compelling investment opportunities for institutional investors looking to capitalize on the expanding immunotherapy landscape.
Analyst Target Price
$123.78
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-15 | 2025-09-08 | 2025-06-02 | 2025-03-24 | 2024-11-07 | 2024-09-09 | 2024-04-02 | 2024-02-06 | 2023-11-29 | 2023-09-21 |
| Reported EPS | -2.47 | -0.89 | -0.95 | -0.8143 | -0.72 | -1.01 | -0.7903 | 0 | -0.64 | -0.72 |
| Estimated EPS | -0.79 | -0.95 | -0.76 | -1.29 | -0.79 | -0.97 | -0.6 | -0.92 | -0.64 | 0 |
| Surprise | -1.68 | 0.06 | -0.19 | 0.4757 | 0.07 | -0.04 | -0.1903 | 0.92 | 0 | -0.72 |
| Surprise Percentage | -212.6582% | 6.3158% | -25% | 36.876% | 8.8608% | -4.1237% | -31.7167% | 100% | 0% | None% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-23 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.7 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABVX
2026-03-05 06:52:30
ABIVAX Société Anonyme (ENXTPA:ABVX) recently released new preclinical and Phase 3 data for its lead drug obefazimod at ECCO 2026, leading to increased attention on its valuation. Despite a significant 1-year total shareholder return, the company's share price of €99.5 is near analyst targets. Simply Wall St's analysis suggests that an 15.1x Price-to-Book ratio is overvalued, and a Discounted Cash Flow model indicates the shares are trading above their estimated fair value of €32.19, raising questions about current buying opportunities given the company's unprofitability.
2026-03-04 12:52:30
TD Asset Management Inc has acquired 46,486 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, valued at approximately $3.95 million. This purchase brings their total ownership to about 0.06% of the company, contributing to the 47.91% of the stock held by institutional investors. Abivax, a clinical-stage biopharmaceutical company, is focused on developing therapies for inflammatory diseases and viral infections, with a lead asset, obefazimod, currently being evaluated for ulcerative colitis.
2026-03-04 08:51:36
Short interest in Abivax SA Sponsored ADR (NASDAQ:ABVX) decreased by 13.2% in February, totaling 3,172,758 shares. This represents a days-to-cover ratio of 4.7 days based on average daily trading volume. Institutional investors and hedge funds have adjusted their positions, with several major firms increasing their stakes, while analysts hold a "Moderate Buy" rating with an average target price of $134.75.
2026-03-01 10:05:14
Envestnet Asset Management Inc. has acquired a new stake of 20,300 shares in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, valued at approximately $1.72 million. This move is part of broader institutional interest in Abivax, with other firms like Boothbay Fund Management, Nan Fung Trinity, and Federated Hermes also increasing or initiating significant positions, bringing institutional ownership to about 47.91%. Analysts have a consensus "Moderate Buy" rating for Abivax with an average target price of $134.75, despite one firm retaining a "sell" rating.
2026-02-28 10:53:14
This page provides a comprehensive overview of ABVX (Abivax) stock news, earnings, and events. Key highlights include recent clinical data presentations for its drug obefazimod at the ECCO Congress, discussions around a significant stock surge, and past rumors concerning Eli Lilly's potential acquisition of Abivax. The information is presented to help investors track company developments and market sentiment.
2026-02-27 11:35:00
Abivax SA (ABVX) is a clinical-stage biotech company focused on treating chronic inflammatory diseases, with its lead drug candidate obefazimod in Phase 3 trials for ulcerative colitis and Phase 2b for Crohn’s disease. Despite financial challenges including negative profitability and revenue growth, analysts are optimistic, projecting a 29.91% potential upside. The company's stock is supported by strong analyst "buy" ratings and technical indicators suggesting an upward trend, making it an intriguing, high-risk, high-reward investment opportunity.
